Mint.Under an agreement with US drug developer, Serum Institute will develop two billion doses of Novavax's vaccine candidate annually.
The drugmaker will also manufacture the antigen component of the vaccine. Novavax is currently conducting late-stage trials in Britain and expects to report resulby the first quarter of 2021."We have also partnered with US based Codagenix, which is in its pre-clinical trials phase and will move to the human trial phase by the end of 2020," Adar Poonawalla, chief executive officer, told Mint. "We have a global manufacturing and supply association with them," he further revealed."We are also researching on two candidates for the coronavirus vaccine," Poonawalla told Mint.